FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Cassava Sciences Inc. (NASDAQ:SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company’s trial for simufilamFollowing previously reported communications with the FDA regarding Cassava’s investigational new drug application and proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex (TSC)-related epilepsy, the company confirmed a full FDA clinical hold.The SEC filing highlighted that the company has to provide the FDA with additional ...